FDA approval for Abecma® Recognized with Donation to Leukemia & Lymphoma Society
Thermo Fisher Scientific has made a donation to the Leukemia & Lymphoma Society in recognition of the recent FDA approval of Abecma®. The lentiviral vector used to engineer patients’ T cells was manufactured at Thermo Fisher’s viral vector manufacturing site in Cambridge, Mass. The FDA approval provides the site with a commercial license for viral vector manufacturing.
Read Press Release »
Thermo Fisher Recognized with Six CMO Leadership Awards
Thermo Fisher Scientific has been recognized with six awards in the annual CMO Leadership Awards, presented by Life Science Leader and Outsourced Pharma. The awards recognize top contract manufacturing partners, as evaluated by biopharma and biotech companies. Thermo Fisher won across all six categories, including: Capabilities, Compatibility, Expertise, Quality, Reliability and Service. This is the second consecutive year Thermo Fisher has received this recognition across all six categories.
Read Press Release »
Thermo Fisher Acquires Henogen S.A.
To accelerate demand for cell and gene vaccines and therapies globally, Thermo Fisher and Groupe Novasep SAS (Novasep) announced that Thermo Fisher has acquired Henogen S.A., Novasep’s viral vector manufacturing business in Belgium. With two locations in Seneffe and Gosselies, Belgium, Novasep’s viral vector business has more than 7,000 m2 of state-of-the-art clinical and commercial manufacturing capacity and approximately 400 employees with substantial operational and technical expertise in a broad range of viral vector classes.
Learn More »
Thermo Fisher to Expand Plasmid DNA Manufacturing
To accelerate commercialization of plasmid-based medicines and vaccines, Thermo Fisher is constructing a new cGMP plasmid DNA manufacturing facility in Carlsbad, CA. The new site will expand the company’’s clinical and commercial capabilities for cGMP plasmid DNA used as a critical raw material to develop and manufacture cell and gene-based therapies including life-saving cancer treatments and mRNA vaccines. The site will also have the capability to produce large-scale plasmid DNA as a primary drug substance for DNA therapies.
Learn More »
Thermo Fisher Expands Clinical Supply Chain Services in Europe
To meet accelerating demand for robust clinical supply chain services throughout Europe, Thermo Fisher has expanded its pharma services footprint with two new state-of-the-art facilities in Rheinfelden and Weil am Rhein, Germany. The new sites will bring much-needed clinical supply chain continuity and specialized cold chain and cryogenic expertise across Europe and globally. These new facilities feature innovative and highly automated technologies to optimize efficiency and quality across the pharma services supply chain.
Learn More »
Thermo Fisher to Expand Global Steriles in North America and Europe
To meet the rapidly growing global demand for injectable sterile drugs, Thermo Fisher is further expanding its pharma services footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines. Over the next two years, expansion projects at our sites in Greenville, NC, Ferentino and Monza, Italy, and Swindon, UK, will add 15 development and commercial production lines to support a range of capabilities, including live virus, aseptic liquid and lyophilized vial filling, to further enhance our global steriles network.
Learn More »
